---
document_datetime: 2024-11-22 13:38:42
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tecovirimat-siga-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: tecovirimat-siga-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.8104735
conversion_datetime: 2025-12-15 01:10:00.190959
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Tecovirimat SIGA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                               |
|----------------------|-----------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10971 /202401  | Periodic Safety Update EU Single assessment - tecovirimat | 19/09/2024                          | 14/11/2024                                  | PL                               | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10971/202401.                            |
| S/0010               | Annual re-assessment.                                     | 30/05/2024                          | n/a                                         |                                  | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                |            |            |             | medicinal product, concluded that marketing authorisation of Tecovirimat SIGA should be maintained.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10971 /202307 | Periodic Safety Update EU Single assessment - tecovirimat                                                                                                                                                                                                                                      | 08/02/2024 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| S/0004              | Annual re-assessment.                                                                                                                                                                                                                                                                          | 12/10/2023 | 07/12/2023 | Annex II    | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Tecovirimat SIGA should be varied, updating Annex II with a new specific obligation: 'To ensure adequate monitoring of safety and efficacy of Tecovirimat in the treatment of the Smallpox, Mpox, Cowpox viral infections and complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg, the MAH shall provide yearly updates on any new information concerning |
| II/0006             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 12/10/2023 | 07/12/2023 | Annex II    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| PSUSA/10971 /202301 | Periodic Safety Update EU Single assessment - tecovirimat                                                                                                                                                                                                                                      | 31/08/2023 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0005             | Update of section 4.2 of the SmPC in order to introduce a new posology regimen for those with a body weight of 120 kg and above based on final                                                                                                                                                 | 26/04/2023 | 31/05/2023 | SmPC and PL | As a result of this variation, sections 4.1, 4.2 and 5.1 of the SmPC are being updated to add the new posology and to change monkeypox to mpox.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | results from study SIGA-246-022 and study report 865, which is a PopPK modelling and simulation report. Study SIGA-246-022 is a multiple-dose, open-label, safety, tolerability, and pharmacokinetic study of tecovirimat in adults weighing more than 120 kg. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                             |            |     | For more information, please refer to the Summary of Product Characteristics.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------|
| II/0003/G | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 16/03/2023 | n/a |                                                                                 |

<div style=\"page-break-after: always\"></div>

| IB/0007             | B.II.a.3.z - Changes in the composition (excipients) of the finished product - Other variation                                                                                                                         | 15/03/2023   | 31/05/2023   | SmPC   |                                                                                                                                                                                                                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10971 /202207 | Periodic Safety Update EU Single assessment - tecovirimat                                                                                                                                                              | 09/02/2023   | n/a          |        | PRAC Recommendation - maintenance                                                                                                                                                                                      |
| IB/0001             | The RMP has been updated to include follow up forms and communication for prescribers (DHPC) for use in pregnancy and lactation and use in immunocompromised subjects in line with the agency request in the D195 JAR. | 20/07/2022   | n/a          |        | The RMP has been updated to include follow up forms and communication for prescribers (DHPC) for use in pregnancy and lactation and use in immunocompromised subjects in line with the agency request in the D195 JAR. |